![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Ablynx and the National Research Council Canada Sign Deal
Ablynx and the National Research Council Canada Sign Deal
May 27, 2005
Ablynx, a pioneer in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments, announced that it has signed a collaborative research, development and license agreement with the Ottawa-based National Research Council of Canada (NRC) Institute for Biological Sciences (IBS).This collaboration will make an important contribution to Ablynx's discovery efforts in the area of neurodegenerative diseases.
()a href="http://www.pharmalive.com/News/index.cfm?articleid=243415&categoryid=15" target="_blank">PharmaLive
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct